

Date: September 29, 2023

To,
The Manager- Listing Department,
National Stock Exchange of India Limited, Exchange Plaza, Plot
No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai - 400051
Scrip Code: REMUS

Dear Sir,

Sub: Intimation of Trading Window Closure of Remus Pharmaceuticals Limited.

This is to inform that, in accordance with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Designated persons and pursuant to the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 as amended from time to time, the Trading window for trading in securities of the Company by the directors, designated persons and their immediate relatives shall remain closed from Sunday, October 01, 2023 till 48 hours after the declaration of Financial Results of the company for the half year ended September 30, 2023.

The date of Board Meeting to consider the financial results for the half year ended September 30, 2023 shall be intimated in due course.

You are requested to kindly take the above information on your record.


Thanking you

Yours faithfully,

For, Remus Pharmaceuticals Limited

Arpit Deepakkumar Shah
Digitally signed by Arpit Deepakkumar Shah
Date: 2023.09.29 17:52:59 +05'30'

Arpit Deepakkumar Shah
Managing Director
DIN: 07214641



Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.

P: 079 2999 9857

USA OFFICE: 5900 Balcones Drive, STE 100 Austin, TX 78731

P: +1 6096 320 320

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: U24232GJ2015PLC084536